[Clinical efficacy and safety of norfloxacin tablets in pediatrics].
We have evaluated norfloxacin (NFLX) tablets for therapeutic effectiveness and safety in children. The results are summarized as follows. 1. A clinical study was performed on 14 children with infections, including 12 with urinary tract infections and 2 with acute bronchitis. Doses ranging from 1.7 to 5.4 mg/kg body weight were given b.i.d. or t.i.d.. Lengths of treatment ranged from 3 to 15 days. The therapeutic responses were considered "excellent" in 8 and "good" in 5, with an efficacy rate of 93%. 2. Side effects were observed in 2 cases, one with light-headed feeling and one with vomiting. In clinical laboratory tests, eosinophilia was found in 2 cases and GOT was slightly elevated in 1 case. It has been concluded that NFLX is a usable drug for the treatment of bacterial infections in children.
Morita
H
H
Department of Pediatrics, Kochi Medical School.
Tomoda
T
T
Araki
K
K
Kurashige
T
T
Nishibayashi
Y
Y
Matsumoto
K
K
Zushi
N
N
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D001991:Bronchitis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013607:Tablets; D014552:Urinary Tract Infections / Q000188:drug therapy*
D013607:Tablets; D009643:Norfloxacin